news
Press release
 
October 1, 2018
Corindus Technology Successfully used in Multiple Live Complex Robotic-Assisted Coronary Interventions at Transcatheter Cardiovascular Therapeutics 2018

Cases broadcast live to thousands of TCT attendees from University of Washington Medical Center and UC San Diego using the CorPath® GRX System

WALTHAM, MA – October 1, 2018 Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that its CorPath GRX System was used for multiple complex robotic-assisted percutaneous coronary interventions (PCI) at the recent Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference. In the first case at University of Washington Medical Center, Dr. William Lombardi, a high volume chronic total occlusion (CTO) PCI operator, performed the first live transmission of a hybrid CTO PCI using both manual and robotic techniques to successfully treat a patient suffering from a complete coronary artery blockage. Simultaneously, at UC San Diego, Dr. Ehtisham Mahmud performed a robotic-assisted CHIP (Complex Higher-Risk Indicated Patients) case utilizing multiple interventional devices. Both demonstrations were broadcast live during TCT to thousands of conference attendees. Recordings of the live cases can be viewed by visiting tctmd.com/tct2018.

In addition, the first live transmission of a remote robotic demonstration was streamed from Mayo Clinic using CorPath GRX with developmental remote technology, giving Dr. Gurpreet Sandhu the ability to remotely manipulate interventional devices within a porcine model’s arteries while located in a different building.

William Lombardi, M.D., Interventional Cardiologist at the University of Washington Medical Center, stated, “The robot’s ability to precisely manipulate devices, specifically the controlled movement of the guide, is very impressive. Since incorporating robotics into my program, I’ve been able to reduce my time in lead by almost 40% which is especially valuable for the long, complex cases I perform.”

Mark Toland, President and Chief Executive Officer of Corindus, stated, “This year’s TCT meeting celebrated 30 years of groundbreaking science and innovation. We are pleased that advanced vascular robotic technology and its role in complex interventions was a prevalent theme throughout the conference.”

About Transcatheter Cardiovascular Therapeutics (TCT)

TCT is the world’s largest and most important educational meeting specializing in interventional cardiovascular medicine. For 30 years, TCT has been the center of cutting-edge educational content, showcasing the latest advances in current therapies and clinical research. The symposium is designed for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by- millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: our ability to expand our technology platform and achieve the advances necessary for telestenting and remote procedures, including in humans; our ability to expand our technology platform for use in other segments of the vascular intervention market, including neurointerventional and other more complex cardiac interventions; obtaining necessary regulatory approvals for the use on humans and marketing of our products in the United States and in other countries; risks associated with market acceptance; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; and potential safety and regulatory issues that could slow or suspend our sales. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at www.corindus.com.

Media Contacts:

Trevi Communications

Lisa Murray
T: 978-750-0333 ext. 2
lisa@trevicomm.com

Investor Relations Contact:

In-Site Communications, Inc.

Lisa Wilson
T: 917-543-9932
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.







right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window